S01 E02
Surgibots Podcast

The Benefits of Surgical Robotics 

On Episode 2 of The Surgibots Podcast we spoke to David Fischel, the Chairman and CEO of Stereotaxis, about the benefits of surgical robotics for patients and surgeons.

The Benefits of Surgical Robotics 

ALSO AVAILABLE ON

SpotifyApple podcastsAmazon music
Share
Surgibots Ep 2 Blog

The Benefits of Surgical Robotics 

On Episode 2 of The Surgibots Podcast we spoke to David Fischel, the Chairman and CEO of Stereotaxis, about the benefits of surgical robotics for patients and surgeons. David joined Sterotaxis after a successful career in the financial industry, where he specialised in medical device venture capital and healthcare hedge fund investments. After seeing Stereotaxis’ innovation and potential, David transitioned into a business management role to help the company take their surgical robot for minimally invasive heart surgery to the next stage.  

What's the effect on the patient when surgery is performed mechanically compared to when it's done robotically? 

The vast majority of our clinical experience has been in one specific type of endovascular surgery called cardiac ablation, which is a procedure used to treat arrhythmias. In the procedure, if the heart is not beating regularly, catheters are navigated into the heart chambers. There are a subset of interventional cardiologists focused on arrhythmia and heart rhythm disorders, and they're able to use electrogrammes, mapping systems and other diagnostic tools to determine where the misbehaving heart muscles are that are causing this irregularity. They can then use an ablation catheter, typically with an RF energy, to ablate that tissue and isolate the misbehaving heart muscle cells.  

That's a very common procedure - there are about 1.2 million of those a year around the world. You have to control the tip in a very precise way and get your blade in the right spot to treat the arrhythmia. If you put the blade in the wrong spot you can cause significant damage to the patient, so you have to take direct control of the tip and hold the catheter in a very steady position against the tissue. With the robots, you can do all of that with a very soft and gentle catheter, which has a much lower risk of mechanically harming the patient. In addition, the physician is now doing this entire procedure from a computer cockpit, so they're not exposed to radiation from the X ray system. All of those factors provide value.  

One of our physicians uses the system predominantly in paediatric and complex congenital patients. People who had a congenital heart disease had many surgeries over their childhood, and because of that, they often develop an arrhythmia as they become older. In those patients, it's often difficult to navigate the abnormal anatomy, because the tissue is thicker where it’s been adjusted through several surgeries. Surgeons often have difficulty reaching where they need to, but the robotic catheter can be steered through the twists and turns with great precision, reaching areas that would otherwise be unreachable. This technology is allowing surgeons to treat patients that otherwise would have no other options.  

What other benefits are there for using the Genesis system? 

 I'd say the two biggest benefits are the reduction of risk and to the ability to treat patients that otherwise have no options. With the reduction of risk, there is a reduction in major adverse events for patients because of the very soft, gentle catheter that is being navigated through the blood vessels into the heart. That creates a much lower risk of complications than with rigid catheter, where if the physician makes one sudden move it could perforate the heart or dissect the vessel. The reduction of major adverse events leads to significant saving overall for the health system.  

For physicians, it allows them to keep operating as they get older. If their hands are less stable due to age or illness, our system allows them to minimise the risks that that poses to their patients. The loss of a physician is a significant burden on society, so being able to reduce the risk for both patients and physicians provides widespread societal savings.  

The overall burden on the health system of a patient with a severe arrhythmia is relatively high. They'll be hospitalised multiple times, they'll be on various drug therapies that have relatively poor efficacy etc, so when you can do an ablation procedure that treats them definitively, that is highly beneficial for everyone. When you can provide therapy to patients that otherwise wouldn't be able to be treated, that provides a huge benefit as well. 

To hear more about the work of Stereotaxis’ surgical robots, tune into The Surgibots Podcast here.  

 

 

LISTEN ON YOUR FAVOURITE PODCAST PLATFORM
SpotifyApple podcastsAmazon music

More episodes in this industry

What's the Hype with Neuro? A Lesson in the Brain - With Hannah Claridge
Podcast43

What's the Hype with Neuro? A Lesson in the Brain - With Hannah Claridge

In this episode, your host, Henry Norton, is joined by Hannah Claridge, the Head of Neurotechnology at TTP, to talk about the incredible advancements that are being made to treat neurological conditions. Hannah points out how complex the brain and nervous systems are, with both relying on intricate connections. She also explores the new technologies that are being developed to treat nervous disorders, such as spinal cord stimulation. She also compared neurotechnologies to pharmaceuticals, highlighting the parallels and differences in how they interact with the body. Hannah also suggested that neurotherapy will be key to the advancement of treatments for conditions like depression, due to their ability to provide targeted and long-term relief of symptoms. Cybersecurity is also a major concern for neurotechnology, as any malfunction or deliberate interference could have serious ramifications for patients.
Why Most Medtech Fundraisers Fail and What to Do Instead - Kiko Filipov, Partner at APPARIUS
Podcast42

Why Most Medtech Fundraisers Fail and What to Do Instead - Kiko Filipov, Partner at APPARIUS

Raising capital in Medtech is tougher than ever. Investor expectations have shifted. Competition is up. And many founders are still pitching like it’s 2018. In this episode, Henry Norton sits down with Kiko Filipov, Partner at APPARIUS Corporate Finance and Strategic Advisor at Cruxx, to unpack the real mechanics of a successful fundraise in 2025. From first-in-human data to commercial readiness, Kiko shares what separates the rounds that get oversubscribed from the ones that stall. He also explores the changing landscape of Medtech innovation and why strategic exits take years of planning, how emerging markets are joining the race, and where VCs are placing bets across surgical robotics, neurostimulation, and digital health. Whether you're gearing up for Series A or preparing your pitch deck, this episode delivers tactical clarity from someone who’s in the room with both founders and funds.

Discover more about Medical Devices